Calusterone

DB01564

small molecule experimental illicit

Deskripsi

A 17-alkylated orally active androgenic steroid. A Schedule IV drug in Canada.

Struktur Molekul 2D

Berat 316.4776
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

149 Data
Prasterone The serum concentration of Calusterone can be increased when it is combined with Prasterone.
Dextrose, unspecified form The serum concentration of Dextrose, unspecified form can be decreased when it is combined with Calusterone.
Propranolol Calusterone may increase the excretion rate of Propranolol which could result in a lower serum level and potentially a reduction in efficacy.
Flunisolide The risk or severity of edema formation can be increased when Calusterone is combined with Flunisolide.
Beclomethasone dipropionate The risk or severity of edema formation can be increased when Calusterone is combined with Beclomethasone dipropionate.
Betamethasone The risk or severity of edema formation can be increased when Calusterone is combined with Betamethasone.
Fluticasone propionate The risk or severity of edema formation can be increased when Calusterone is combined with Fluticasone propionate.
Fluocinolone acetonide The risk or severity of edema formation can be increased when Calusterone is combined with Fluocinolone acetonide.
Triamcinolone The risk or severity of edema formation can be increased when Calusterone is combined with Triamcinolone.
Prednisone The risk or severity of edema formation can be increased when Calusterone is combined with Prednisone.
Fludrocortisone The risk or severity of edema formation can be increased when Calusterone is combined with Fludrocortisone.
Hydrocortisone The risk or severity of edema formation can be increased when Calusterone is combined with Hydrocortisone.
Prednisolone The risk or severity of edema formation can be increased when Calusterone is combined with Prednisolone.
Methylprednisolone The risk or severity of edema formation can be increased when Calusterone is combined with Methylprednisolone.
Trilostane The risk or severity of edema formation can be increased when Calusterone is combined with Trilostane.
Budesonide The risk or severity of edema formation can be increased when Calusterone is combined with Budesonide.
Dexamethasone The risk or severity of edema formation can be increased when Calusterone is combined with Dexamethasone.
Corticotropin The risk or severity of edema formation can be increased when Calusterone is combined with Corticotropin.
Cortisone acetate The risk or severity of edema formation can be increased when Calusterone is combined with Cortisone acetate.
Paramethasone The risk or severity of edema formation can be increased when Calusterone is combined with Paramethasone.
Ciclesonide The risk or severity of edema formation can be increased when Calusterone is combined with Ciclesonide.
Aldosterone The risk or severity of edema formation can be increased when Calusterone is combined with Aldosterone.
Fluticasone furoate The risk or severity of edema formation can be increased when Calusterone is combined with Fluticasone furoate.
Fluprednidene The risk or severity of edema formation can be increased when Calusterone is combined with Fluprednidene.
Tixocortol The risk or severity of edema formation can be increased when Calusterone is combined with Tixocortol.
Fluprednisolone The risk or severity of edema formation can be increased when Calusterone is combined with Fluprednisolone.
Meprednisone The risk or severity of edema formation can be increased when Calusterone is combined with Meprednisone.
Dexamethasone isonicotinate The risk or severity of edema formation can be increased when Calusterone is combined with Dexamethasone isonicotinate.
Melengestrol The risk or severity of edema formation can be increased when Calusterone is combined with Melengestrol.
Deflazacort The risk or severity of edema formation can be increased when Calusterone is combined with Deflazacort.
Cortivazol The risk or severity of edema formation can be increased when Calusterone is combined with Cortivazol.
Prednylidene The risk or severity of edema formation can be increased when Calusterone is combined with Prednylidene.
Fluocortin The risk or severity of edema formation can be increased when Calusterone is combined with Fluocortin.
Fluperolone The risk or severity of edema formation can be increased when Calusterone is combined with Fluperolone.
Cloprednol The risk or severity of edema formation can be increased when Calusterone is combined with Cloprednol.
Fluclorolone The risk or severity of edema formation can be increased when Calusterone is combined with Fluclorolone.
Fluticasone The risk or severity of edema formation can be increased when Calusterone is combined with Fluticasone.
Mometasone furoate The risk or severity of edema formation can be increased when Calusterone is combined with Mometasone furoate.
Hydrocortisone acetate The risk or severity of edema formation can be increased when Calusterone is combined with Hydrocortisone acetate.
Hydrocortisone cypionate The risk or severity of edema formation can be increased when Calusterone is combined with Hydrocortisone cypionate.
Hydrocortisone succinate The risk or severity of edema formation can be increased when Calusterone is combined with Hydrocortisone succinate.
Prednisolone phosphate The risk or severity of edema formation can be increased when Calusterone is combined with Prednisolone phosphate.
Prednisolone hemisuccinate The risk or severity of edema formation can be increased when Calusterone is combined with Prednisolone hemisuccinate.
Methylprednisolone hemisuccinate The risk or severity of edema formation can be increased when Calusterone is combined with Methylprednisolone hemisuccinate.
Prednisone acetate The risk or severity of edema formation can be increased when Calusterone is combined with Prednisone acetate.
Clocortolone acetate The risk or severity of edema formation can be increased when Calusterone is combined with Clocortolone acetate.
Melengestrol acetate The risk or severity of edema formation can be increased when Calusterone is combined with Melengestrol acetate.
Betamethasone phosphate The risk or severity of edema formation can be increased when Calusterone is combined with Betamethasone phosphate.
Cortisone The risk or severity of edema formation can be increased when Calusterone is combined with Cortisone.
Clobetasol propionate The risk or severity of edema formation can be increased when Calusterone is combined with Clobetasol propionate.
Fluocinonide The risk or severity of edema formation can be increased when Calusterone is combined with Fluocinonide.
Hydrocortisone butyrate The risk or severity of edema formation can be increased when Calusterone is combined with Hydrocortisone butyrate.
Desoximetasone The risk or severity of edema formation can be increased when Calusterone is combined with Desoximetasone.
Mometasone The risk or severity of edema formation can be increased when Calusterone is combined with Mometasone.
Fluocortolone The risk or severity of edema formation can be increased when Calusterone is combined with Fluocortolone.
Prednisolone acetate The risk or severity of edema formation can be increased when Calusterone is combined with Prednisolone acetate.
Fluorometholone The risk or severity of edema formation can be increased when Calusterone is combined with Fluorometholone.
Difluocortolone The risk or severity of edema formation can be increased when Calusterone is combined with Difluocortolone.
Flumethasone The risk or severity of edema formation can be increased when Calusterone is combined with Flumethasone.
Methylprednisolone aceponate The risk or severity of edema formation can be increased when Calusterone is combined with Methylprednisolone aceponate.
Lepirudin Calusterone may increase the anticoagulant activities of Lepirudin.
Bivalirudin Calusterone may increase the anticoagulant activities of Bivalirudin.
Alteplase Calusterone may increase the anticoagulant activities of Alteplase.
Urokinase Calusterone may increase the anticoagulant activities of Urokinase.
Reteplase Calusterone may increase the anticoagulant activities of Reteplase.
Anistreplase Calusterone may increase the anticoagulant activities of Anistreplase.
Tenecteplase Calusterone may increase the anticoagulant activities of Tenecteplase.
Abciximab Calusterone may increase the anticoagulant activities of Abciximab.
Drotrecogin alfa Calusterone may increase the anticoagulant activities of Drotrecogin alfa.
Streptokinase Calusterone may increase the anticoagulant activities of Streptokinase.
Dicoumarol Calusterone may increase the anticoagulant activities of Dicoumarol.
Argatroban Calusterone may increase the anticoagulant activities of Argatroban.
Ardeparin Calusterone may increase the anticoagulant activities of Ardeparin.
Phenindione Calusterone may increase the anticoagulant activities of Phenindione.
Fondaparinux Calusterone may increase the anticoagulant activities of Fondaparinux.
Warfarin Calusterone may increase the anticoagulant activities of Warfarin.
Pentosan polysulfate Calusterone may increase the anticoagulant activities of Pentosan polysulfate.
Phenprocoumon Calusterone may increase the anticoagulant activities of Phenprocoumon.
Dipyridamole Calusterone may increase the anticoagulant activities of Dipyridamole.
Heparin Calusterone may increase the anticoagulant activities of Heparin.
Enoxaparin Calusterone may increase the anticoagulant activities of Enoxaparin.
Epoprostenol Calusterone may increase the anticoagulant activities of Epoprostenol.
Acenocoumarol Calusterone may increase the anticoagulant activities of Acenocoumarol.
4-hydroxycoumarin Calusterone may increase the anticoagulant activities of 4-hydroxycoumarin.
Coumarin Calusterone may increase the anticoagulant activities of Coumarin.
Ximelagatran Calusterone may increase the anticoagulant activities of Ximelagatran.
Desmoteplase Calusterone may increase the anticoagulant activities of Desmoteplase.
Defibrotide Calusterone may increase the anticoagulant activities of Defibrotide.
Ancrod Calusterone may increase the anticoagulant activities of Ancrod.
Beraprost Calusterone may increase the anticoagulant activities of Beraprost.
Prasugrel Calusterone may increase the anticoagulant activities of Prasugrel.
Rivaroxaban Calusterone may increase the anticoagulant activities of Rivaroxaban.
Sulodexide Calusterone may increase the anticoagulant activities of Sulodexide.
Semuloparin Calusterone may increase the anticoagulant activities of Semuloparin.
Idraparinux Calusterone may increase the anticoagulant activities of Idraparinux.
Cangrelor Calusterone may increase the anticoagulant activities of Cangrelor.
Astaxanthin Calusterone may increase the anticoagulant activities of Astaxanthin.
Apixaban Calusterone may increase the anticoagulant activities of Apixaban.
Otamixaban Calusterone may increase the anticoagulant activities of Otamixaban.
Amediplase Calusterone may increase the anticoagulant activities of Amediplase.

Target Protein

Androgen receptor AR

Referensi & Sumber

Artikel (PubMed)
  • PMID: 1501542
    Meli RJ, Ros PR: MR appearance of intra-abdominal metastatic melanoma. Magn Reson Imaging. 1992;10(4):705-8.

Contoh Produk & Brand

Produk: 0 • International brands: 2
International Brands
  • Methosarb
  • Riedemil

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul